<DOC>
	<DOCNO>NCT00896363</DOCNO>
	<brief_summary>The purpose study test GSK163090 reduce symptom depression . The safety well body handle drug also investigate . The study conduct Russia hospitalise patient severe depression . GSK163090 compare placebo , look like study drug contain active substance . Subjects give either study drug match placebo .</brief_summary>
	<brief_title>Safety Efficacy Study Patients With Major Depressive Disorder</brief_title>
	<detailed_description>This randomise , multi-centre , double-blind , placebo-controlled , repeat dose , parallel group study male female patient severe depression require hospitalization . Efficacy , safety tolerability assess three treatment arm . The study consist screening period , treatment phase ( 6 week ) post-treatment follow-up visit . The study duration screen follow approximately 9 week . Subjects pass screen randomize Day 1 one three treatment arm ( low dose arm , high dose arm placebo ) . Each treatment arm contain approximately 50 subject . The subject 's depressive symptom assess use HAMD17- CR .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Currently severe depression ( Major Depressive Disorder without psychotic feature ) meet criterion ( DSM IVTR ) current major depressive episode least 4 week great 24 month depression questionnaire ( HAMD17 ) total score great equal 24 subject must read able give write informed consent male female 18 64 year use appropriate birth control method BMI 18.8 35.0 kg/m2 ( inclusive ) Primary diagnosis psychiatric disorder thought kill one self someone else take psychiatric medicine therapy within six month Has previously fail adequate course medication MDD two different class antidepressant . Unstable medical disorder disorder would interfere action drug Abuse alcohol drug Past history serotonin syndrome history clinical significant intolerance SSRIs ( class drug use depression ) . History migraine headache respond treatment triptan medication . History clinically significant abnormality neurological system ( include dementia cognitive disorder significant head injury ) history seizure ( exclude febrile seizure ) . Currently take part another clinical study do within six month Pregnant , plan become pregnant shortly breastfeed History sensitivity study medication , component thereof history drug allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>anti-depressant</keyword>
	<keyword>Severe Depression</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Major Depressive Episode</keyword>
</DOC>